<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-YHIZYGBJ/c9ba9a7b-cc55-4674-9ff1-3a3f2437105f/PDF"><dcterms:extent>482 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-YHIZYGBJ/333d9c1c-7ede-4370-8dd8-381755075fd9/TEXT"><dcterms:extent>25 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-YHIZYGBJ"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2016</dcterms:issued><dc:creator>Gašperlin, Mirjana</dc:creator><dc:creator>Kogej, Ksenija</dc:creator><dc:creator>Kristl, Julijana</dc:creator><dc:creator>Lapanje, Aleš</dc:creator><dc:creator>Mirtič, Janja</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:67</dc:format><dc:format xml:lang="sl">str. 310-317</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:4103281</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-YHIZYGBJ</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">dostavni sistemi</dc:subject><dc:subject xml:lang="en">drug</dc:subject><dc:subject xml:lang="sl">farmacevtski preparati</dc:subject><dc:subject xml:lang="sl">ionske interakcije</dc:subject><dc:subject xml:lang="sl">kompleksiranje</dc:subject><dc:subject xml:lang="sl">Nanotehnologija</dc:subject><dc:subject xml:lang="sl">polielektroliti</dc:subject><dc:subject xml:lang="sl">prirejeno sproščanje</dc:subject><dc:subject xml:lang="sl">zdravila</dc:subject><dc:subject rdf:resource="http://www.wikidata.org/entity/Q7649708" /><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Polielektrolitni kompleksi kot osnova za razvoj novih nanodelcev in nanooblog| Polyelectrolyte complexes as a platform for development of novel nanoparticles and nanocoatings|</dc:title><dc:description xml:lang="sl">Polyelectrolyte complexes are based on ionic interaction between the charged polymer (polyelectrolyte) and the substance with the opposite charge, which can be a polymer, a protein, a surfactant or any other charged substance. Active pharmaceutical ingredients that fall in any of the aforementioned categories, can be incorporated into these complexes based on the electrostatic interaction, or can be simply physically entrapped into the complex during its formation. The polyelectrolyte complex formation is spontaneous, although it is important to take into the consideration many different parameters that can affect it. Amongst them the most important one is the charge ratio of the components, which has crucial impact on the colloidal stability of the formed complexes. This concept of complexation can be used in the development of functional polymer drug delivery systems, where the nanodelivery systems are very well investigated, w here polyelectrolyte complexation can enable the controlled drug release, the protection of the drug from degradation or targeted drug delivery</dc:description><dc:description xml:lang="sl">Nastanek polielektrolitnih kompleksov temelji na ionskih interakcijah med ioniziranim polimerom (polielektrolitom) in spojino z nasprotnim nabojem, ki je lahko polimer, protein, površinsko aktivna snov oziroma katera koli spojina z nabojem. Zdravilne učinkovine lahko spadajo v katero od naštetih kategorij in se v te komplekse vgradijo na osnovi ionskih interakcij, lahko pa so vgrajene preprosto z mehanskim ujetjem med nastankom kompleksa. Nastanek polielektrolitnih kompleksov je spontan, vendar je treba pri oblikovanju upoštevati številne dejavnike, med katerimi je najpomembnejše prav razmerje nabojev ioniziranih skupin, ki odločilno vpliva na koloidno stabilnost nastalih kompleksov. Za ugotavljanje mehanizma kompleksiranja in vrednotenje nastalih kompleksov so znane številne metode. Polielektrolitni kompleksi so pogosto predmet raziskav in uporabe predvsem kot funkcionalni polimerni dostavni sistemi učinkovin. Pri zadnjih so v ospredju predvsem nanodostavni sistemi, kjer so polielektrolitni kompleksi osnova za njihov nastanek ter omogočajo prirejeno sproščanje učinkovin, njihovo zaščito pred razgradnjo in ciljano dostavo</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-YHIZYGBJ"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-YHIZYGBJ" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-YHIZYGBJ/c9ba9a7b-cc55-4674-9ff1-3a3f2437105f/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-YHIZYGBJ/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-YHIZYGBJ" /></ore:Aggregation></rdf:RDF>